Portal de Periódicos da CAPES

Successful Treatment of Hepatitis C, Genotype 3, Treatment Failure (Sofosbuvir/Daclatasvir) with Sofosbuvir/Velpatasvir in Decompensated Cirrhosis Complicated by Renal Insufficiency

2019; Volume: 5; Issue: 2 Linguagem: Inglês

10.23937/2469-584x/1510070

2469-584X

Marco Distefano, Marco Lorenza Di, Scifo Enzo, Gruttadauria Salvo, Scifo Gaetano, Marco Vito Di,

Systemic Lupus Erythematosus Research

Clinical trials and real word data have proven that chronic hepatitis C (HCV) can be eradicated (sustained virological response SVR or 'cure') in the majority of patients by direct - acting antivirals (DAAs) . There are, however, groups of patients in whom HCV treatment outcomes with direct acting antivirals (DAAs) are suboptimal (genotype (GT) 3 patients, decompensated cirrhosis, renal failure) or have not been studied in large cohorts (patients with relapse to a previous DAAs treatment (failure)). This case outlines the successful eradication of GT-3 hepatitis C (HCV) in a patient with decompensated cirrhosis and renal failure secondary to diabetes after DAA failure, using a 24-week course of sofosbuvir, velpatasvir and ribavirin. The achievement of SVR in this patient resulted in significant improvement in hepatic function.